Falk Center for Molecular Therapeutics, Biomedical Engineering, Northwestern University, Evanston, Illinois, USA.
Aptinyx, Inc., Evanston, Illinois, USA.
J Neurochem. 2020 Mar;152(5):523-541. doi: 10.1111/jnc.14845. Epub 2019 Oct 16.
N-methyl-d-aspartate receptors (NMDARs) mediate both physiological and pathophysiological processes, although selective ligands lack broad clinical utility. NMDARs are composed of multiple subunits, but N-methyl-d-aspartate receptor subunit 2 (GluN2) is predominately responsible for functional heterogeneity. Specifically, the GluN2A- and GluN2B-containing subtypes are enriched in adult hippocampus and cortex and impact neuronal communication via dynamic trafficking into and out of the synapse. We sought to understand if ((2S, 3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5-diazaspiro[3,4]octan-2-yl) butanamide (NYX-2925), a novel NMDAR modulator, alters synaptic levels of GluN2A- or GluN2B-containing NMDARs. Low-picomolar NYX-2925 increased GluN2B colocalization with the excitatory post-synaptic marker post-synaptic density protein 95 (PSD-95) in rat primary hippocampal neurons within 30 min. Twenty-four hours following oral administration, 1 mg/kg NYX-2925 increased GluN2B in PSD-95-associated complexes ex vivo, and low-picomolar NYX-2925 regulated numerous trafficking pathways in vitro. Because the NYX-2925 concentration that increases synaptic GluN2B was markedly below that which enhances long-term potentiation (mid-nanomolar), we sought to elucidate the basis of this effect. Although NMDAR-dependent, NYX-2925-mediated colocalization of GluN2B with PSD-95 occurred independent of ion flux, as colocalization increased in the presence of either the NMDAR channel blocker (5R,10S)-(-)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate or glycine site antagonist 7-chlorokynurenic acid. Moreover, while mid-nanomolar NYX-2925 concentrations, which do not increase synaptic GluN2B, enhanced calcium transients, functional plasticity was only enhanced by picomolar NYX-2925. Thus, NYX-2925 concentrations that increase synaptic GluN2B facilitated the chemical long-term potentiation induced insertion of synaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor GluA1 subunit levels. Basal (unstimulated by chemical long-term potentiation) levels of synaptic GluA1 were only increased by mid-nanomolar NYX-2925. These data suggest that NYX-2925 facilitates homeostatic plasticity by initially increasing synaptic GluN2B via metabotropic-like NMDAR signaling. Cover Image for this issue: doi: 10.1111/jnc.14735.
N-甲基-D-天冬氨酸受体(NMDAR)介导生理和病理生理过程,尽管选择性配体缺乏广泛的临床实用性。NMDAR 由多个亚基组成,但 N-甲基-D-天冬氨酸受体亚基 2(GluN2)主要负责功能异质性。具体而言,富含成年海马体和皮质的 GluN2A 和 GluN2B 亚型通过动态进入和离开突触来影响神经元通讯。我们试图了解新型 NMDAR 调节剂 ((2S,3R)-3-羟基-2-((R)-5-异丁酰基-1-氧代-2,5-二氮杂螺[3,4]辛烷-2-基)丁酰胺(NYX-2925)是否会改变突触中 GluN2A 或 GluN2B 包含的 NMDAR 水平。低皮摩尔浓度的 NYX-2925 在大鼠原代海马神经元中,在 30 分钟内增加了 GluN2B 与兴奋性突触后标记物突触后密度蛋白 95(PSD-95)的共定位。口服给药 24 小时后,1mg/kg 的 NYX-2925 增加了 PSD-95 相关复合物中外源性 GluN2B,并且低皮摩尔浓度的 NYX-2925 在体外调节多种运输途径。因为增加突触 GluN2B 的 NYX-2925 浓度明显低于增强长时程增强(中纳摩尔)的浓度,所以我们试图阐明这种效应的基础。尽管 NYX-2925 介导的 GluN2B 与 PSD-95 的共定位依赖于 NMDAR 依赖性,但离子流独立发生,因为在存在 NMDAR 通道阻滞剂(5R,10S)-(-)-5-甲基-10,11-二氢-5H-二苯并[a,d]环庚烯-5,10-亚胺马来酸或甘氨酸位点拮抗剂 7-氯犬尿氨酸时,共定位增加了。此外,虽然中纳摩尔浓度的 NYX-2925 不会增加突触 GluN2B,但增强了钙瞬变,而只有皮摩尔浓度的 NYX-2925 增强了功能可塑性。因此,增加突触 GluN2B 的 NYX-2925 浓度促进了化学长时程增强诱导的突触α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体 GluA1 亚基水平的插入。仅中纳摩尔浓度的 NYX-2925 增加了基础(未通过化学长时程增强刺激)水平的突触 GluA1。这些数据表明,NYX-2925 通过最初通过代谢型样 NMDAR 信号增加突触 GluN2B 来促进同型可塑性。本期的封面图片:doi:10.1111/jnc.14735。